AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. AzaSite(®) utilizes a vehicle delivery system called DuraSite(®), which stabilizes and sustains the release of azithromycin to the ocular surface, leading t...

purpose: compaison of excyclotorsion induced by horizontal transposition of vertical rectus muscles versus vertical transposition of horizontal rectus muscles in rabbit eyes. methods: in this exprimental study, group 1 underwent full tendon nasal transposition of the superior rectus and full tendon temporal transposition of the inferior rectus (10 adult rabbits); group 2 underwent superior tran...

BACKGROUND The purpose of this study was to evaluate the effect of daily administration of mannitol-enriched sodium hyaluronate ophthalmic solution on the corneal optical properties of subjects wearing low Dk hydrogel (etafilcon A) contact lenses (CLs). METHODS Forty-five subjects wearing etafilcon A CLs daily for more than 6 months were recruited into this pilot study. Fifteen of the subject...

PURPOSE The objective of this study was to collect and evaluate retrospective safety information about the use of besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial keratitis. METHODS This was a retrospective, postmarketing surveillance study conducted at 10 clinical centers in the United States. The study population included 142 patients treated with besifloxacin ophthalm...

PURPOSE To analyze the effect of azithromycin 1% ophthalmic solution in DuraSite (InSite Vision, Inc, Alameda, California, USA) on bacterial conjunctivitis. DESIGN Prospective, randomized, vehicle-controlled, parallel-group, double-masked multicenter clinical study. METHODS Eligible male or female participants with a clinical diagnosis of acute bacterial conjunctivitis were randomized to ei...

BACKGROUND We investigated indications and early postoperative treatment for Ex-PRESS(®) insertion for glaucoma by comparing postoperative outcomes with those for standard trabeculectomy. METHODS Ex-PRESS insertion was performed in 21 eyes and standard trabeculectomy (TLE) in 22 eyes. Mean intraocular pressure (IOP) in the 6 months after surgery, success rate for postoperative IOP decline, po...